Diagnostic Application Segment to Grow at Faster Pace During Forecast Period

According to a new market research study of “Asia Pacific  Exosome Diagnostic and Therapeutic Market 2027 – Regional Analysis and Forecast by Application, Product, and End User,” the Asia Pacific  exosome diagnostic and therapeutic market is projected to reach US$ 75,730.50 thousand by2027 from US$ 8,311.42 thousand in 2019. The market is estimated to grow at CAGR of 33.1% from 2020 to 2027. The report highlights trends prevailing in the Asia Pacific  exosome diagnostic and therapeutic market and the factors driving market along with those that act as hindrances. In recent effectiveness of stem cell therapy in corona virus patients is presenting some positive opportunities in future. For instance, Researchers in China administered COVID-19 patients with a mesenchymal stem cell therapy that demonstrated success at treating the condition. Early findings are promising this treatment can be continued as a long-term study in more patients worldwide.

The Asia Pacific exosome diagnostic and therapeutic market, based on application, is further segmented into diagnostic and therapeutic. The diagnostic segment held a larger share of the market in 2019. Also, the diagnostic segment is estimated to register a higher CAGR during the forecast period owing greater precision and advantages over traditional methods of diagnosis and therapeutics and increasing awareness of procedural outcomes served by exosomes. Increasing awareness about exosomes diagnostics is propelling the companies to enter into this market to tap lucrative opportunities. For instance, the rising cancer population in the country is driving demand of exosome based diagnostic therapies. Moreover, For instance, exosomes released from tumor cells contains tumor-specific RNAs that can be potentially detected during cancer diagnosis. These carrier exosomes can also be used as biomarkers in the diagnosis of neurodegenerative and metabolic disorders, and infectious and other diseases.

The Asia Pacific exosome diagnostic and therapeutic market is expected to grow owing to factors such as greater precision and advantages over traditional methods of diagnosis and therapeutics and increasing number of research activities in the field of exosomes. However, poor infrastructure and lack of expertise required for isolation of exosomes are likely to restrain the growth of the market during the forecast period.

Leading companies operating in the exosome diagnostic and therapeutic market are Aethlon Medical, Inc., ReNeuron Group plc, Immune Therapy Holdings AB, Cell Guidance Systems LLC, BioRegenerative Sciences, Evomic Science LLC, NorgenBiotek Corp., Exosome Diagnostics, Inc. Bio-Techne, and MiltenyiBiotec, among others.

Asia Pacific  Exosome Diagnostic and Therapeutic Market, By Country, 2019 (%)

The report segments Asia Pacific exosome diagnostic and therapeutic market as follows:

By Application

• Diagnostic
• Therapeutic

By Product

• Instruments
• Reagents
• Software

By End User

• Cancer Institutes
• Hospitals
• Diagnostic Centers
• Others

By Country

• Japan
• China
• India
• South Korea
• Australia